Who is sponsoring NCT03007875?

NCT03007875 is sponsored by Fuda Cancer Hospital, Guangzhou.

What drugs are being tested in NCT03007875?

Interventions in NCT03007875: high-activity natural killer.

What condition does NCT03007875 study?

NCT03007875 studies Non-small Cell Lung Cancer Metastatic.

Is NCT03007875 still recruiting?

NCT03007875 is currently completed. Last updated 12 September 2019.

Last reviewed 2019-09-12 · How we verify

NCT03007875

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

High-activity Natural Killer Immunotherapy for Small Metastases of Non-small Cell Lung Cancer

Completed Phase 1, PHASE2 Last updated 12 September 2019

What this trial tests

Phase 1, PHASE2 trial testing high-activity natural killer in Non-small Cell Lung Cancer Metastatic in 20 participants. Completed in 1 September 2019.

Timeline

1 December 2016

Primary endpoint
1 December 2017

1 September 2019

Quick facts

Lead sponsor	Fuda Cancer Hospital, Guangzhou
Phase	Phase 1, PHASE2
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	20
Start date	1 December 2016
Primary completion	1 December 2017
Estimated completion	1 September 2019
Sites	1 location across China

Drugs / interventions tested

high-activity natural killer — full drug profile →

Conditions studied

Non-small Cell Lung Cancer Metastatic — all drugs for Non-small Cell Lung Cancer Metastatic →

Sponsor

Fuda Cancer Hospital, Guangzhou

Who can join

Adults 30 to 60, any sex, with Non-small Cell Lung Cancer Metastatic. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The aim of this study is the safety and efficacy of high-activity natural killer immunotherapy to small metastases of non-small cell lung cancer.

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

Bioengineering and Clinical Translation of Human Lung and its Components.
Derman ID, Singh YP, Saini S, Nagamine M, et al · · 2023 · cited 8× · PMID 36658734 · DOI 10.1002/adbi.202200267
Molecular characterization of circulating tumor cells in lung cancer: moving beyond enumeration.
Wang L, Dumenil C, Julié C, Giraud V, et al · · 2017 · cited 3× · PMID 29312651 · DOI 10.18632/oncotarget.22651
Natural Killer Cells in Cancers of Respiratory System and Their Applications in Therapeutic Approaches.
Dokhanchi M, Javaherdehi AP, Raad M, Khalilollah S, et al · · 2024 · cited 2× · PMID 39588940 · DOI 10.1002/iid3.70079

Verify or expand the search:

Other recruiting trials for Non-small Cell Lung Cancer Metastatic

Currently open trials in the same condition.

NCT07292168 — A Phase 1b/2 Study of the Safety and Efficacy of the Monoclonal Antibody OM-RCA-01 in Patients With Metastatic Tumors Ex · Phase 1, PHASE2 · recruiting
NCT06517953 — Befotertinib and Icotinib for NSCLC With Uncommon EGFR Mutations · Phase 2 · recruiting
NCT04563338 — An Exploratory Study of Atezolizumab and Bevacizumab in Hepatocellular Carcinoma and Non-Small Cell Lung Cancer With Liv · Phase 2 · active not recruiting
NCT04836728 — Phase II Study of Chemotherapy and PD-1 Inhibitor Combination With Autologous CIK Cell Immunotherapy to Treat Lung Cance · Phase 2 · active not recruiting
NCT04504071 — Dacomitinib in Lung Cancer With Uncommon EGFR Mutations · Phase 2 · active not recruiting

Other Fuda Cancer Hospital, Guangzhou trials

Trials by the same sponsor.

NCT04393220 — Combination of PD-1 and VEGFR-2 Blockade for Advanced Hepatocellular Carcinoma · Phase 2 · completed
NCT03673137 — Phase II/III of Randomized Controlled Clinical Research on IRE Synchronous Chemotherapy for LAPC · Phase 2, PHASE3 · completed
NCT03976206 — Very Small Embryonic-like Stem Cells for Facial Skin Antiaging · Phase 1, PHASE2 · withdrawn
NCT03975101 — Very Small Embryonic-like Stem Cells for Knee Osteoarthritis · Phase 1, PHASE2 · withdrawn
NCT03985462 — Very Small Embryonic-like Stem Cells for Ovary · Phase 1, PHASE2 · withdrawn

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03007875 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Fuda Cancer Hospital, Guangzhou
Last refreshed: 12 September 2019

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03007875.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing